SCHEMBL6404353

SCHEMBL6404353

O=C(CCCc1ccc(O)cc1)c1ccc(O)cc1OP(=O)(O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
ACHE P22303 2/20 0.44
SGMS1 Q86VZ5 2/20 0.44
SGMS2 Q8NHU3 2/20 0.44
S1PR1 P21453 2/20 0.43
CYP19A1 P11511 2/20 0.40
DPP4 P27487 1/20 0.40
HTT P42858 1/20 0.40
ESR1 P03372 2/20 0.39
SHBG P04278 1/20 0.39
ESR2 Q92731 1/20 0.39
KDM4E B2RXH2 1/20 0.38
SLC16A3 O15427 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TTR P02766 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396785 0.92 MEN1 (0.68) MEN1KMT2ACYP19A1ESR1SHBG
SCHEMBL6898518 0.90 MEN1 (0.48) MEN1KMT2AACHESGMS1SGMS2
SCHEMBL6403588 0.89 MEN1 (0.45) MEN1KMT2AS1PR1DPP4HTT
SCHEMBL6396368 0.83 ESR1 (0.58) MEN1KMT2AHTTESR1SHBG
SCHEMBL6397107 0.82 ACHE (0.61) MEN1KMT2AACHESGMS1SGMS2
SCHEMBL6404104 0.81 MEN1 (0.57) MEN1KMT2ACYP19A1ESR1KDM4E
SCHEMBL6397597 0.81 ESR1 (0.48) MEN1KMT2AACHECYP19A1ESR1
SCHEMBL6397770 0.81 ESR1 (0.44) MEN1KMT2AACHESGMS1SGMS2
SCHEMBL6396603 0.81 MEN1 (0.53) MEN1KMT2ACYP19A1AKR1B10AKR1B1
SCHEMBL6403797 0.80 MEN1 (0.48) MEN1KMT2AACHESGMS1SGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885KMT2A 4852/4885ACHE 4868/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MEN1 2179/4885KMT2A 4828/4885ACHE 4865/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885KMT2A 4852/4885ACHE 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.